Long‐term treatment experience in a subject with Dunnigan‐type familial partial lipodystrophy: efficacy of rosiglitazone
Authors:
- 19 October 2005
- journal article
- case report
- Published by Wiley in Diabetic Medicine
- Vol. 22 (11) , 1611-1613
Abstract
Dunnigan-type familial partial lipodystrophy (FPLD) is caused by mutations in LMNA, the gene that encodes nuclear lamins A and C. FPLD is characterized by peripheral fat loss, excess central adiposity, insulin resistance, and hyperlipidaemia, which are difficult to treat. We present our 2 years' experience of treatment with rosiglitazone in a subject with FPLD. Insulin requirement decreased significantly from 240 IU/day to 76 IU/day (range 20-240 IU/day) and serum triglyceride concentration was lowered from 13.7 +/- 14.4 mmol/l to 4.5 +/- 4.3 mmol/l and remained stable. Mean HbA(1c) prior to rosiglitazone therapy was 9.4 +/- 1.32% and decreased to 7.4 +/- 0.6% during therapy with rosiglitazone. This case demonstrates the benefits of PPARgamma-agonists on glycaemic control and dyslipidaemia in a patient with FPLD. This in turn implies that PPARgamma may play a pathophysiological role in FPLD.Keywords
This publication has 10 references indexed in Scilit:
- Patients with Familial Partial Lipodystrophy of the Dunnigan Type Due to aLMNAR482W Mutation Show Muscular and Cardiac AbnormalitiesThe Journal of Clinical Endocrinology & Metabolism, 2004
- Combination Therapy With Fenofibrate and Rosiglitazone Paradoxically Lowers Serum HDL CholesterolDiabetes Care, 2004
- Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA geneDiabetic Medicine, 2003
- Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitusAdvanced Drug Delivery Reviews, 2002
- Dyslipemia in Familial Partial Lipodystrophy Caused by an R482W Mutation in the LMNA GeneThe Journal of Clinical Endocrinology & Metabolism, 2001
- Dyslipemia in Familial Partial Lipodystrophy Caused by an R482W Mutation in the LMNA GeneThe Journal of Clinical Endocrinology & Metabolism, 2001
- Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy.Diabetes, 2000
- Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy SyndromesAnnals of Internal Medicine, 2000
- Lipodystrophy of the extremities. A dominantly inherited syndrome associated with lipatrophic diabetesHuman Genetics, 1975
- Familial Lipoatrophic Diabetes with Dominant TransmissionA NEW SYNDROME1QJM: An International Journal of Medicine, 1974